Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Fulcrum Therapeutics (Nasdaq: FULC) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 10:30 a.m. ET / 7:30 a.m. PT.
A live webcast will be accessible via Fulcrum's Events and Presentations page and a replay will be available on the company's website for at least 30 days following the presentation.
Positive
- None.
Negative
- None.
News Market Reaction – FULC
In the Jan 7 session, FULC declined 0.10%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 10 | Equity offering priced | Negative | -5.5% | Upsized $175M stock and pre-funded warrant offering under effective registration. |
| Dec 08 | Equity offering planned | Negative | +46.0% | Proposed $150M common stock offering with $22.5M underwriter option. |
| Dec 06 | Clinical data update | Positive | +46.0% | Positive Phase 1b PIONEER pociredir data in sickle cell disease at ASH. |
| Dec 05 | Inducement grant | Neutral | +0.3% | Nasdaq Rule 5635(c)(4) stock option grant to a new employee. |
| Dec 02 | Investor event notice | Positive | -9.3% | Scheduled investor event to review new PIONEER trial clinical data. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has triggered large but mixed reactions: strong positive moves on clinical data and one offering announcement, contrasted with selloffs on another offering and a data-preview event, indicating inconsistent market responses to capital raises and clinical communications.
Over the last month, Fulcrum has balanced financing and clinical catalysts. A proposed $150.0M offering on Dec 8, 2025 and its upsized $175.0M pricing on Dec 10, 2025 showed sharply different price reactions. Positive Phase 1b PIONEER data for pociredir in sickle cell disease on Dec 6, 2025 coincided with a strong gain, while a Dec 2, 2025 investor event announcement on the same trial saw a notable decline. The current JPM conference participation fits into this pattern of frequent investor-facing events.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that company management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 14, 2026 at 10:30 a.m. ET/7:30 a.m. PT.
A live webcast of the presentation will be accessible HERE or by visiting the "Events and Presentations" section of Fulcrum Therapeutics’ website at https://ir.fulcrumtx.com/events-and-presentations. A replay of the webcast will be available on Fulcrum Therapeutics’ website for at least 30 days following the presentation.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on X (@FulcrumTx) and LinkedIn.
Contact:
Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
617-283-2856
